Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis

Table 4 Subgroup analysis between the low-dose CNI group and the standard-dose CNI group

Outcomes	Low-dose CNI				Standard-dose CNI				Subgroup differences
Outcomes	Number of trials	Number of patients	RR/WMD	95% CI	Number of trials	Number of patients	RR/WMD	95% CI	p value	Heterogeneity p value (%)
1-year AR rate	2	135	0.57	0.27, 1.17	2	62	3	0.51, 17.82	0.09	65.4
1-year graft survival rate	1	103	0.98	0.92, 1.05	2	62	1	0.9, 1.11	0.77	0
DGF rate	1	103	0.98	0.26, 3.71	1	42	0.29	0.07, 1.22	0.22	33.7
1-year infection rate	2	135	0.6	0.4, 0.88	2	62	0.82	0.41, 1.63	0.43	0
Renal graft function postsurgery at 12 months	2	135	−2.96	−11.12, 5.21	2	62	1.05	−7.88, 9.97	0.52	0

MSCs mesenchymal stromal cells, AR acute rejection, DGF delay graft function, RR risk ratio, WMD weighted mean difference, CI confidence intervals

ISSN: 1757-6512